Erratum: Progress in antifungal therapy: Echinocandins versus azoles (DOI:10.1016/j.ddstr.2006.06.001);Progress in antifungal therapy: Echinocandins versus azoles

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 2, 2006, Pages 221-226

  Nailor, Michael D ^a,b   Sobel, Jack D ^b  

^a DETROIT RECEIVING HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ASPARTATE AMINOTRANSFERASE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CASPOFUNGIN; CISAPRIDE; CYCLOSPORIN; ECHINOCANDIN; ERGOT ALKALOID; FLUCONAZOLE; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; MICAFUNGIN; NIFEDIPINE; POLYENE; POSACONAZOLE; PYRROLE DERIVATIVE; QUINIDINE; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; TACROLIMUS; UNINDEXED DRUG; VORICONAZOLE;

ANEMIA; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; BLURRED VISION; CANDIDIASIS; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; ESOPHAGUS CANDIDIASIS; FEBRILE NEUTROPENIA; HEADACHE; HUMAN; HYPOALBUMINEMIA; IN VITRO STUDY; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NAUSEA; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PHLEBITIS; PHOTOPHOBIA; REVIEW; STEVENS JOHNSON SYNDROME; VISUAL DISORDER;

EID: 33746820225     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.10.002     Document Type: Erratum

References (36)

1. Manavathu E.L., et al. Organism-dependent fungicidal activities of azoles. Antimicrob. Agents Chemother. 42 (1998) 3018-3021
2. Law D., et al. Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob. Agents Chemother. 41 (1997) 2310-2311
3. Torres H.A., et al. Posaconazole: a broad spectrum triazole antifungal. Lancet Infect. Dis. 5 (2005) 775-785
4. Denning D.W. Echinocandin antifungal drugs. Lancet 362 (2003) 1142-1151
5. McCormack P.L., and Perry C.M. Caspofungin: a review of its use in the treatment of fungal infections. Drugs 65 (2005) 2049:68
6. Carver P.L. Micafungin. Ann. Pharmacother. 38 (2004) 1707-1721
7. Vasquez J.A. Anidulafungin: a new echinocandin with a novel profile. Clin. Ther. 27 (2005) 657-673
8. Trifilio S., et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 35 (2005) 509-513
9. Purkins L. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br. J. Clin. Pharmacol. 56 (2003) S10-S16
10. Johnson L.B., and Kauffman C.A. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. 36 (2002) 630-637
11. De Beule K., and Van Gestel J. Pharmacology of itraconazole. Drugs 61 (2001) S27-S37
12. Debruyne D., and Ryckelynck J. Clinical pharmacokinetics of fluconazole. Clin. Pharmacokinet. 24 (1993) 10-27
13. National Committee for Clinical Laboratory Standards (2002) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard NCCLS Document M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA
14. Ostrosky-Zeichner L., et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47 (2003) 3149-3154
15. Pfaller M.A., et al. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J. Clin. Microbiol. 44 (2006) 760-763
16. Pfaller M.A., et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4, 169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Mycology 48 (2004) 201-205
17. Sun Q.N. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob. Agents Chemother. 46 (2002) 1581-1582
18. Villanueva A., et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med. 113 (2002) 294-299
19. Krause D.S., et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis. 39 (2004) 770-775
20. Marr K.A., et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporine A. Transplant. Infect. Dis. 6 (2004) 110-116
21. Sanz-Rodriguez C. Safety of the concomitant use of caspofungin and cyclosporine A in patients with invasive fungal infections. Bone Marrow Transplant. 13 (2004) 13-20
22. Ally R., et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin. Infect. Dis. 33 (2001) 1447-1454
23. Pappas P.G., et al. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38 (2004) 161-189
24. Kullberg B.J., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366 (2005) 1435-1442
25. Reboli A. et al. (2005) Anidulafungins versus fluconazole for treatment of candidemia and invasive candidiasis. 45th Interscience Conference of Antimicrobial Agents and Chemotherapy, 16-19 December 2002, Washington, DC, p. 418 (Abstract M-718)
26. Mora-Duarte J., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347 (2002) 2020-2029
27. Spellberg B.J., et al. Current treatment strategies for disseminated candidiasis. Clin. Infect. Dis. 42 (2006) 244-251
28. van Burik J.A., et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis. 39 (2004) 1407-1416
29. Pelz R.K., et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann. Surg. 233 (2001) 542-548
30. Garbino J., et al. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med. 28 (2002) 1708-1717
31. Ostrosky-Zeichner L., and Pappas P.G. Invasive candidiasis in the intensive care unit. Crit. Care Med. 34 (2006) 857-863
32. Ullmann A.J., et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob. Agents Chemother. 50 (2006) 658-666
33. Imhof A., et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin. Infect. Dis. 39 (2004) 743-746
34. Walsh T.J., et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 351 (2004) 1391-1402
35. Walsh T.J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. 346 (2002) 225-234
36. Golan Y., et al. Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis. Ann. Intern. Med. 143 (2005) 857-869